Tabelecleucel for Allogeneic Haematopoietic Stem-Cell or Solid Organ Transplant Recipients With Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE): A Phase 3, Mult

0
35
The authors aimed to determine the clinical benefit of tabelecleucel in patients with relapsed or refractory Epstein–Barr virus-positive post-transplant lymphoproliferative disease following HSCT or solid organ transplant.
[Lancet Oncology]
Abstract